# Treatment of Hemorrhagic Fever With Ribavirin

> **NCT04283513** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 50 (estimated)

## Conditions studied

- Hemorrhagic Fever

## Interventions

- **DRUG:** Virazole

## Key facts

- **NCT ID:** NCT04283513
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-31
- **Primary completion:** 2026-04
- **Final completion:** 2027-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04283513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04283513, "Treatment of Hemorrhagic Fever With Ribavirin". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04283513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*